Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNE-101 in Acute Ischemic Stroke
NCT06995625Phase 1Recruiting
- Sponsor
- S&E bio
- Start
- Jun 2026
- Primary completion
- Mar 2027
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SNE-101 in ischemic stroke, sponsored by S&E bio. Primary endpoints: Maximum Tolerated Dose at 19 days and Adverse Events at 180 days. Started Jun 2026; status: recruiting.
02
Drugs
SNE-101
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06995625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06995625.